143 related articles for article (PubMed ID: 2017196)
1. A novel process for preparing an acellular pertussis vaccine composed of non-pyrogenic toxoids of pertussis toxin and filamentous hemagglutinin.
Tan LU; Fahim RE; Jackson G; Phillips K; Wah P; Alkema D; Zobrist G; Herbert A; Boux L; Chong P
Mol Immunol; 1991 Mar; 28(3):251-5. PubMed ID: 2017196
[TBL] [Abstract][Full Text] [Related]
2. Simple, efficient purification of filamentous hemagglutinin and pertussis toxin from Bordetella pertussis by hydrophobic and affinity interaction.
Skelton SK; Wong KH
J Clin Microbiol; 1990 May; 28(5):1062-5. PubMed ID: 2351723
[TBL] [Abstract][Full Text] [Related]
3. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
[TBL] [Abstract][Full Text] [Related]
4. The purification and characterization of an acellular pertussis vaccine.
Chazono M; Yoshida I; Konobe T; Fukai K
J Biol Stand; 1988 Apr; 16(2):83-9. PubMed ID: 2897370
[TBL] [Abstract][Full Text] [Related]
5. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
[TBL] [Abstract][Full Text] [Related]
6. Serum antibody response to B. pertussis Tn5 mutants, purified PT and FHA in two different mouse strains and passive protection in the murine intranasal infection model.
Olander RM; Muotiala A; Karvonen M; Kuronen T; Runeberg-Nyman K
Microb Pathog; 1990 Jan; 8(1):37-45. PubMed ID: 2159104
[TBL] [Abstract][Full Text] [Related]
7. Preparation of filamentous hemagglutinin from Bordetella pertussis and assay for serum antibodies to filamentous hemagglutinin and pertussis toxin for clinical and public health laboratories.
Wong KH; Skelton SK
J Clin Microbiol; 1989 Dec; 27(12):2805-10. PubMed ID: 2556434
[TBL] [Abstract][Full Text] [Related]
8. Acellular pertussis vaccine prepared by a simple extraction and toxoiding procedure.
Christodoulides M; Sidey FM; Parton R; Stewart-Tull DE
Vaccine; 1987 Sep; 5(3):199-207. PubMed ID: 2890244
[TBL] [Abstract][Full Text] [Related]
9. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
Sato Y; Sato H
Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin.
Kimura M; Kuno-Sakai H; Kamiya H; Ueda K; Isomura S; Koike M; Kato T; Ozaki T; Hirose M; Egami T
Acta Paediatr Jpn; 1995 Oct; 37(5):562-74. PubMed ID: 8533580
[TBL] [Abstract][Full Text] [Related]
11. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
[TBL] [Abstract][Full Text] [Related]
12. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
13. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
Novotny P; Chubb AP; Cownley K; Charles IG
Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model.
Watanabe M; Komatsu E; Abe K; Iyama S; Sato T; Nagai M
Vaccine; 2002 Jan; 20(9-10):1429-34. PubMed ID: 11818163
[TBL] [Abstract][Full Text] [Related]
15. Protective activities in mice of monoclonal antibodies against pertussis toxin.
Sato H; Sato Y
Infect Immun; 1990 Oct; 58(10):3369-74. PubMed ID: 1698179
[TBL] [Abstract][Full Text] [Related]
16. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
Thomas MG; Ashworth LA; Miller E; Lambert HP
J Infect Dis; 1989 Nov; 160(5):838-45. PubMed ID: 2572651
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.
Podda A; Nencioni L; Marsili I; Peppoloni S; Volpini G; Donati D; Di Tommaso A; De Magistris MT; Rappuoli R
Vaccine; 1991 Oct; 9(10):741-5. PubMed ID: 1759492
[TBL] [Abstract][Full Text] [Related]
18. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
[TBL] [Abstract][Full Text] [Related]
20. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
Sato H; Sato Y
Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
